15 results
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
and states on innovate payment mechanisms for high-cost cell and gene therapies. While Medicaid is not a significant driver of cell therapy sales
6-K
EX-1
AUTL
Autolus Therapeutics plc
30 Jun 21
Annual Report and Accounts
6:05am
and states on innovate payment mechanisms for high-cost cell and gene therapies. While Medicaid is not a significant driver of cell therapy sales
424B4
AUTL
Autolus Therapeutics plc
11 Apr 19
Prospectus supplement with pricing info
4:10pm
, or PRIME, designation from the European Medicines Agency, or EMA.
Continue to innovate and develop our product pipeline using a modular approach to T cell
F-1
cjepkoqs5 0t
8 Apr 19
Registration statement (foreign)
4:34pm
6-K
EX-1
j20rxmxam
15 Mar 19
Annual Report and Accounts
5:26pm
6-K
EX-99.1
8gge93985 9mi70
25 Feb 19
Current report (foreign)
4:39pm
DRS
wn962
23 Nov 18
Draft registration statement
12:00am
20-F
e7ghh kqup1v
23 Nov 18
Annual report (foreign)
12:00am
424B4
xh1l10
22 Jun 18
Prospectus supplement with pricing info
4:02pm
F-1/A
mv8zdp
19 Jun 18
Registration statement (foreign) (amended)
8:05am
F-1/A
7wx g7d5y2
8 Jun 18
Registration statement (foreign) (amended)
6:25am
F-1/A
nauxict cc
10 May 18
Registration statement (foreign) (amended)
5:19pm
F-1
eet9zae7p
7 May 18
Registration statement (foreign)
4:45pm
- Prev
- 1
- Next